Global Chronic Kidney Disease (CKD) Market, By Product Type (Diagnosis, Treatment), Route of Administration (Oral, Intravenous, Subcutaneous), End Users (Hospitals, Diagnostic Laboratories, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
The chronic kidney disease (CKD) market is expected to gain growth at a potential rate of 5.00% in the forecast period of 2021 to 2028 and is expected to reach a value of USD 20.96 billion by 2028. Increasing cases of kidney failure and advancement in the healthcare industry are the factors for the market growth.
Chronic Kidney Disease (CKD) is also termed as chronic kidney failure which is characterized by gradual loss of kidney function. There are various types of medications available in market. Medicines cannot reverse chronic kidney disease, but they are used to treat complications and to slow further kidney damage.
The rapid increase in prevalence rate of hypertension, diabetes and cardiovascular diseases is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the rise in awareness regarding transplantation therapy and presence of large geriatric population base are also predictable to enhance the chronic kidney disease (CKD) market growth. Furthermore, the favorable reimbursement policies in emerging countries and high degree of R&D activity in expansion of CKD drugs are also projected to drive the market growth rate. Also, due to the high unmet needs, several manufacturers in the market are focusing on innovation and technological advances in treatment, which is also expected to influence the chronic kidney disease (CKD) market growth globally.
In addition, the rapid technological advancement as well as the increase in the rate of R&D initiatives is likely to create various new opportunities that will impact this chronic kidney disease (CKD) market growth in the forecast period of 2021 to 2028.
However, the high cost involved in the treatment and Patent expiry from many companies and introduction of generic drugs are expected to act as major restraints towards the growth of the chronic kidney disease (CKD) market, whereas the poor patient compliance in some countries can challenge the growth of the target market in the above mentioned forecast period.
This chronic kidney disease (CKD) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the chronic kidney disease (CKD) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Chronic Kidney Disease (CKD) Market Scope and Market Size
The chronic kidney disease (CKD) market is segmented on the basis of product type, route of administration, end users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Based on product type, the chronic kidney disease (CKD) market is segmented into diagnosis and treatment. Diagnosis has further been segmented into blood tests, urine tests, imaging tests and others. Treatment has further been segmented into drug class, dialysis and others. Drug class has further been sub-segmented into ACE inhibitors, b-blockers, calcium channel blockers, loop diuretics, erythropoiesis-stimulating agents (ESAs), phosphate binder and others.
- Based on route of administration, the chronic kidney disease (CKD) market is segmented into oral, intravenous and subcutaneous.
- The chronic kidney disease (CKD) market is also segmented on the basis of end users into hospitals, diagnostic laboratories, homecare, specialty clinics and others.
- On the basis of distribution channel, the chronic kidney disease (CKD) market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
Chronic Kidney Disease (CKD) Market Country Level Analysis
The chronic kidney disease (CKD) market is analyzed and market size information is provided by country by product type, route of administration, end users and distribution channel as referenced above.
The countries covered in the chronic kidney disease (CKD) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the chronic kidney disease (CKD) market due to high cost of medication, rapid change in the healthcare reimbursement environment and upsurge in funding by various government agencies and private organizations in healthcare system. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028because of the high incidence of diabetes and hypertension along with the rapid increase in health care spending.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The chronic kidney disease (CKD) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Chronic Kidney Disease (CKD) Market Share Analysis
The chronic kidney disease (CKD) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to chronic kidney disease (CKD) market.
The major players covered in the chronic kidney disease (CKD) market report are Pfizer Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Abbott, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd, Fresenius Medical Care AG & Co. KGaA, Kissei Pharmaceutical Co., Ltd., AbbVie Inc., Allergan, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., AstraZeneca, Johnson & Johnson Services, Inc., Akebia Therapeutics, Inc., Fibro Gen, Inc., and Siemens Healthcare Private Limited among other domestic and global players. Chronic kidney disease (CKD) market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Chronic Kidney Disease (CKD) Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.